Nanostructured Lipid Carriers for Anticancer Drug Delivery: Bridging Preclinical Advances and the Bench-to-Clinic Translational Gap.

Nanostructured lipid carriers (NLCs) are known to improve the delivery of poorly soluble, unstable, rapidly cleared, or systemically toxic anticancer drugs. Their mixed solid- and liquid-lipid matrix can improve drug incorporation, reduce drug expulsion, and support controlled release. Despite encouraging findings across different cancer models, the important question of "Why the strong preclinical promise of NLCs has not yet been translated into clinical oncology?" remains. Unlike published reviews that mainly focus on formulation, characterization, individual administration routes, or tumor-targeting strategies, the current review examines NLC-based anticancer drug delivery from a broader bench-to-clinic translational gap perspective. Specifically, this review connects formulation design and preclinical performance with the practical barriers that influence clinical development of NLCs. Literature was retrieved from PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Google Scholar. The literature search covered publications from 2008 to 2026. The key terms included "nanostructured lipid carrier" OR "nanostructured lipid carriers" OR "NLC" OR "NLCs" OR "solid lipid nanoparticle" OR "lipid nanocarrier" AND "cancer" OR "tumour" OR "tumour" OR "anticancer" OR "antitumor" OR "antitumour" OR "oncology" AND "drug delivery" OR "targeted delivery" OR "co-delivery" OR "pharmacokinetic". The review also evaluates its application in preclinical, clinical and patented NLCs for cancer treatment, which have received comparatively limited attention.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-17
DOI
https://doi.org/10.2174/0113892010508566261112114605
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nanostructured Lipid Carriers for Anticancer Drug Delivery: Bridging Preclinical Advances and the Bench-to-Clinic Translational Gap.

Khairul Akmal Azhar, Chin Siang Kue, Anyanee Kamkaew, Khairunnisa Nabilah Binti Mohamed Hussein et al.
PubMed
Advancements in Transdermal Drug Delivery
article

Nanostructured Lipid Carriers for Anticancer Drug Delivery: Bridging Preclinical Advances and the Bench-to-Clinic Translational Gap.

Khairul Akmal Azhar, Chin Siang Kue, Anyanee Kamkaew, Khairunnisa Nabilah Binti Mohamed Hussein, Wardina Abdul Halim
article en

Abstract

Nanostructured lipid carriers (NLCs) are known to improve the delivery of poorly soluble, unstable, rapidly cleared, or systemically toxic anticancer drugs. Their mixed solid- and liquid-lipid matrix can improve drug incorporation, reduce drug expulsion, and support controlled release. Despite encouraging findings across different cancer models, the important question of "Why the strong preclinical promise of NLCs has not yet been translated into clinical oncology?" remains. Unlike published reviews that mainly focus on formulation, characterization, individual administration routes, or tumor-targeting strategies, the current review examines NLC-based anticancer drug delivery from a broader bench-to-clinic translational gap perspective. Specifically, this review connects formulation design and preclinical performance with the practical barriers that influence clinical development of NLCs. Literature was retrieved from PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Google Scholar. The literature search covered publications from 2008 to 2026. The key terms included "nanostructured lipid carrier" OR "nanostructured lipid carriers" OR "NLC" OR "NLCs" OR "solid lipid nanoparticle" OR "lipid nanocarrier" AND "cancer" OR "tumour" OR "tumour" OR "anticancer" OR "antitumor" OR "antitumour" OR "oncology" AND "drug delivery" OR "targeted delivery" OR "co-delivery" OR "pharmacokinetic". The review also evaluates its application in preclinical, clinical and patented NLCs for cancer treatment, which have received comparatively limited attention.

PubMed
Management and Science University (MY), University of Malaya (MY), Suranaree University of Technology (TH)
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon